Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2012. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a capital structure notification and contains no financial performance data.
Material Changes
The filing details the Company's issued share capital as of February 29, 2012:
- Total issued Ordinary shares: 5,556,265,573 (25p each).
- Treasury shares held: 506,782,927.
- Total voting rights: 5,049,482,646.
This figure is provided to assist shareholders in determining notification requirements under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of voting rights (5,049,482,646) for compliance calculations.
- Confirm the number of shares held in Treasury (506,782,927) to understand the float.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly earnings releases for performance metrics.